Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Junji Tsurutani et al.|New England Journal of Medicine|2022Cited by 2.5k
Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patientsEriko Tokunaga, Yoshihiko Maehara|International Journal of Cancer|2005Cited by 176
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerGiulia Viale, Victoria de Giorgio‐Miller, Mark Basik et al.|ESMO Open|2023Cited by 76